Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.9606 | 0.9606 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 1 | 1 |
Schistosoma mansoni | lamin | 0.0033 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.8593 | 0.8593 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 1 | 0.5 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 1 | 0.5 |
Echinococcus multilocularis | lamin | 0.0033 | 1 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.8593 | 0.5 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.8593 | 0.5 |
Onchocerca volvulus | 0.0033 | 1 | 0.5 | |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.8593 | 0.5 |
Onchocerca volvulus | 0.0033 | 1 | 0.5 | |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.8593 | 0.5 |
Brugia malayi | hypothetical protein | 0.002 | 0.1458 | 0.1458 |
Brugia malayi | hypothetical protein | 0.003 | 0.8593 | 0.8593 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.8593 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 1 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.8593 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.8593 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.8593 | 0.5 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 1 | 1 |
Schistosoma mansoni | lamin | 0.0033 | 1 | 0.5 |
Echinococcus multilocularis | musashi | 0.0033 | 1 | 0.5 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 1 | 1 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 1 | 0.5 |
Schistosoma mansoni | intermediate filament proteins | 0.0033 | 1 | 0.5 |
Echinococcus granulosus | lamin | 0.0033 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.631 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10.4179 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 12.5893 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization. This assay monitors tau fibrillation by fluorescence polarization (FP) of Alexa 594-labeled K18 P301L, which does not fibrillize readily but incorporates into growing filaments of unlabeled tau. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.